Navigation Links
LA BioMed awarded research grant to study HIV prevention gel
Date:4/27/2010

Los Angeles (April 26, 2010) Los Angeles Biomedical Research Institute (LA BioMed) has received a $350,000 grant to study the safety of a gel designed to reduce the heterosexual transmission of HIV from the International Partnership for Microbicides (IPM), a nonprofit global initiative to develop products to reduce HIV transmission, and the U.S. Agency for International Development (USAID), the Institute announced today.

The grant will fund LA BioMed's participation in the IPM020 study of the safety of a dapivirine-containing microbicide gel, which represents the second generation of HIV-prevention products for women. The study is a multicenter trial underway at five U.S. sites that will enroll 180 research volunteers with funding from IPM and USAID.

Susan Ballagh, MD, a LA BioMed principal investigator, and her research team have started recruiting 30 healthy women, ages 18-40, for the LA BioMed study. To participate, the research volunteers will need to use the investigational gel daily for 12 weeks to evaluate its safety and absorption into tissues.

"If this gel is found to be safe, further testing will be undertaken to determine its effectiveness in preventing the transmission of HIV," Dr. Ballagh said. "IPM is committed to providing women with an affordable and self-initiating HIV-prevention strategy. The organization's goal is to reduce the cycle of infection that has led to the deaths of more than 25 million people worldwide and orphaned more than 15 million children since 1981."

Every day, nearly 7,000 people around the world are newly infected with HIV, the virus that causes AIDS, and some 33 million people are now living with HIV, half of them women, according to IPM. The World Health Organization recently reported that AIDS is the No. 1 cause of death and disease among women of reproductive age in the world, with women in developing countries bearing the brunt of the epidemic.

IPM was founded in 2002 to reduce HIV transmission by accelerating the development and availability of a safe and effective microbicide for use by women in developing countries.

Annalene Nel, MD, IPM chief medical officer based in South Africa, will visit LA BioMed on Thursday to review the LA BioMed study site. Dr. Nel is responsible for IPM's clinical trials and international clinical site development.

Previously, she worked as an independent clinical research consultant in the drug development process. She has significant experience in all levels of clinical research and in a broad range of therapeutic areas. She also has worked as an investigator in clinical research for more than 20 years.


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. BioMedix Vascular Solutions, Inc. Invited to Participate in the California P.A.D. Task Force Committee
2. Biomedical Industry Jobs Critical to California's Economic Recovery, Finds California Healthcare Institute and PricewaterhouseCoopers
3. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
4. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
5. Autism-Supplements.com and Generation Rescue Work Together to Raise Money for Biomedical Autism Treatments
6. Lefkowitz, BBVA Foundation Frontiers of Knowledge Award in Biomedicine
7. Money for Biomedical Research Cut in Recent Years
8. ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum
9. BioMedSearch.com Launches
10. The Foundation for Biomedical Research Releases New Breast Cancer PSA
11. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been diagnosed ... surgery, treatment, therapy and management. Regular exercise in proper environments has been shown ... their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx ...
(Date:2/21/2017)... NJ (PRWEB) , ... February 21, 2017 , ... ... research and conference coverage in veterinary medicine, will be launching its first bi-monthly ... animal health and medicine, business and practice management, and One Health. , ...
(Date:2/21/2017)... ... 2017 , ... Atlanta-based Jvion, the leading cognitive clinical science ... practice. Predixion, which raised $42M+ to date, received $20M in its third ... Ventures, and Software AG , will bring top industry talent and an impressive ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... Medical Oxygen Concentrators Market: Overview ... Medical oxygen concentrators are used by patients ... having low level of oxygen in their blood ... are to be used only with prescription and ... concentrators work either on rechargeable lithium batteries or ...
(Date:2/21/2017)...   BeyondSpring Pharmaceuticals , a clinical stage ... immuno-oncology cancer therapies, today announced that the Company,s ... 2 trial of BeyondSpring,s innovative lead asset, ... lung cancer (NSCLC) with Docetaxel has been selected ... Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology: